Full Press Release Details
STOCKHOLM, SE / ACCESS Newswire / October 13, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Chardan Healthcare Conference.
Location: Lotte New York Palace, New York
Format : Panel discussion and 1×1 meetings
Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, CF, Bronchiectasis & COPD Innovation
Date and time: Tuesday, October 20, 2026, 2:00-2:30 PM ET
For further information, please contact: Hans Jeppsson, CFO, +46 (0)70 553 14 65, [email protected]
About Vicore Pharma Holding AB Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
Attachments Vicore Pharma to Participate in the Chardan Healthcare Conference